Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)

2014-07-23 21:08:31 | BioPortfolio


The purpose of this study is to see if bortezomib (Velcade) is effective in the treatment of refractory cGVHD.


Graft vs. host disease represents the most formidable problem following allogeneic hematopoietic stemm cell transplantation for hematological diseases. Chronic graft-versus-host disease (cGVHD) is the most serious and common long-term complication of this treatment in patients surviving more than 100 days. Some patients are requiring immunosuppressive therapy for years. cGVHD is associated with a high degree of morbidity and mortality and remains a major cause of late death. When standard treatment with steroids is ineffective or poorly tolerated, effective therapeutic options are limited. Patients with uncontroled cGVHD with initial therapy including systemic steroids respond poorly to second line options .

Some patients treated with bortezomib to control multiple myeloma after bone marrow transplantation have shown improvement in cGVHD.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Chronic Graft vs Host Disease




Charles A. Cancer Center, Baylor University Medical Center
United States




Baylor Research Institute

Results (where available)

View Results


Published on BioPortfolio: 2014-07-23T21:08:31-0400

Clinical Trials [2655 Associated Clinical Trials listed on BioPortfolio]

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

The purpose of this research study is to determine the effectiveness of bortezomib (Velcade) plus prednisone for treating chronic graft versus host disease (cGVHD) and the safety of this d...

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bon...

A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation

The purpose of this study is determine the highest dose of bortezomib, a new drug for graft-versus host disease prevention, that can be given in combination with sirolimus and Tacrolimus, ...

Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease

This phase II trial studies how well ixazomib citrate works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone...

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-versus-Host Disease

This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment. Chronic graft-ve...

PubMed Articles [22953 Associated PubMed Articles listed on BioPortfolio]

Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease.

Extracorporeal photopheresis (ECP) is a second-line therapy for steroid-refractory chronic graft-versus-host disease (cGVHD).

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated.

Upper gastrointestinal acute graft-versus-host disease is reported in approximately 30% of hematopoietic stem cell transplant recipients developing acute graft-versus-host disease. Currently classifie...

The Association Of Performance Status And Disease Severity In Patients With Chronic Graft-Versus-Host Disease.

Determine the relationship between functional status and degree of specific organ involvement, physical performance, and subjective well-being Chronic graft-versus-host disease (cGVHD) after allogenei...

Resolution of hematocolpos in adolescents affected with Graft Versus Host Disease.

Bone Marrow Transplant (BMT) is a lifesaving procedure for a range of serious benign or malignant hematological conditions. A proportion of patients however will develop Graft Versus Host Disease (GVH...

Eyelid metrics assessment in patients with chronic ocular graft versus-host disease.

To assess eyelid metrics in the setting of chronic ocular graft versus-host disease (oGVHD), and to further correlate them with hematological and ocular characteristics.

Medical and Biotech [MESH] Definitions

An immunological attack mounted by a graft against the host because of tissue incompatibility when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE.

The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.

The immune responses of a host to a graft. A specific response is GRAFT REJECTION.

The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.

Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.

More From BioPortfolio on "Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)"

Quick Search


Relevant Topic

Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Searches Linking to this Trial